Telisotuzumab Vedotin

Last Updated: 06/30/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer.

An evaluation of telisotuzumab vedotin for the treatment of non-squamous non-small cell lung cancer.

Journal: Expert opinion on biological therapy
Published: April 29, 2026

Neurotrophic Keratitis Associated With Telisotuzumab Vedotin: A Case Report.

Neurotrophic Keratitis Associated With Telisotuzumab Vedotin: A Case Report.

Journal: Cornea
Published: April 13, 2026

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors.

Journal: CPT: pharmacometrics & systems pharmacology
Published: January 29, 2026

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.

Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: January 17, 2026

Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.

Emrelis: A New Approach in Treating MET-high Locally Advanced or Metastatic Non-squamous NSCLC; A Mini Review.

Journal: Thoracic research and practice
Published: December 29, 2025

An overview of recent advancements in targeted cancer therapies and their potential clinical impact.

An overview of recent advancements in targeted cancer therapies and their potential clinical impact.

Journal: RSC medicinal chemistry
Published: August 23, 2025

Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?

Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?

Journal: Cancer
Published: August 18, 2025

Telisotuzumab vedotin (Emrelis) for non-small cell lung cancer.

Telisotuzumab vedotin (Emrelis) for non-small cell lung cancer.

Journal: The Medical letter on drugs and therapeutics
Published: July 29, 2025

Evaluating the combined efficacy of Telisotuzumab Vedotin and artificial intelligence in the treatment of non-squamous non-small cell lung cancer: a narrative review focusing on pharmaceutical and technical insights.

Evaluating the combined efficacy of Telisotuzumab Vedotin and artificial intelligence in the treatment of non-squamous non-small cell lung cancer: a narrative review focusing on pharmaceutical and technical insights.

Journal: Frontiers in oncology
Published: July 26, 2025

Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC).

Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC).

Journal: Drug discoveries & therapeutics
Published: July 13, 2025

Telisotuzumab Vedotin: First Approval.

Telisotuzumab Vedotin: First Approval.

Journal: Drugs
Published: June 26, 2025

MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.

MET Alterations in Cancer and MET-Targeted Therapy: Detection Strategies, Treatment Efficacy, and Emerging Technologies.

Journal: Targeted oncology
Published: June 25, 2025
Showing 1-12 of 37

Last Updated: 06/30/2026